Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nusinersen OLIP-02 in SMA
NCT07846696Phase 3Not yet recruiting
- Start
- Sep 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 3 trial of nusinersen in spinal muscular atrophy (SMA). Planned start Sep 2026; status: not yet recruiting.
02
Drugs
nusinersen
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT07846696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07846696.